Protective effects of human lactoferrin during aggregatibacter actinomycetemcomitans-Induced bacteremia in lactoferrin-Deficient mice

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 1, 2014, Pages 397-404

  Velusamy, S K ^a   Poojary, R ^a   Ardeshna, R ^a   Alabdulmohsen, Waad ^a   Fine, D H ^a   Velliyagounder, K ^a  

^a RUTGERS SCHOOL OF DENTAL MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 1BETA; INTERLEUKIN 6; LACTOFERRIN; MYELOPEROXIDASE; TUMOR NECROSIS FACTOR ALPHA;

ACUTE PHASE RESPONSE; AGGREGATIBACTER ACTINOMYCETEMCOMITANS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC PROPHYLAXIS; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BACTEREMIA; BACTERIAL CLEARANCE; BACTERIAL COUNT; BASOPHIL; CELL MIGRATION; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG LIVER LEVEL; DRUG MECHANISM; DRUG SPLEEN LEVEL; DRUG TISSUE LEVEL; EOSINOPHIL; GENE EXPRESSION; HUMAN; IN VIVO STUDY; LYMPHOCYTE; MALE; MONOCYTE; MOUSE; NEUTROPHIL; NONHUMAN; POST EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; SHAM PROCEDURE; SPLEEN WEIGHT;

AGED, 80 AND OVER; AGGREGATIBACTER ACTINOMYCETEMCOMITANS; ANIMALS; BACTEREMIA; C-REACTIVE PROTEIN; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-12; INTERLEUKIN-1BETA; INTERLEUKIN-6; LACTOFERRIN; MALE; MICE, KNOCKOUT; NITRIC OXIDE SYNTHASE TYPE II; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84891501352     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00020-13     Document Type: Article

References (50)

1. Kinane DF, Riggio MP, Walker KF, MacKenzie D, Shearer B. 2005. Bacteraemia following periodontal procedures. J. Clin. Periodontol. 32: 708-713. http://dx.doi.org/10.1111/j.1600-051X.2005.00741.x.
2. Dajani AS, Taubert KA, Wilson W, Bolger AF, Bayer A, Ferrieri P, Gewitz MH, Shulman ST, Nouri S, Newburger JW, Hutto C, Pallasch TJ, Gage TW, Levison ME, Peter G, Zuccaro G, Jr. 1997. Prevention of bacterial endocarditis: recommendations by the American Heart Association. Clin. Infect. Dis. 25:1448-1458. http://dx.doi.org/10.1086/516156.
3. Actor JK, Hwang SA, Kruzel ML. 2009. Lactoferrin as a natural immune modulator. Curr. Pharm. Des. 15:1956-1973. http://dx.doi.org/10.2174/ 138161209788453202.
4. Ahmad G, Sial GZ, Ramadori P, Dudas J, Batusic DS, Ramadori G. 2011. Changes of hepatic lactoferrin gene expression in two mouse models of the acute phase reaction. Int. J. Biochem. Cell Biol. 43:1822-1832. http://dx.doi.org/10. 1016/j.biocel.2011.09.002.
5. Teraguchi S, Shin K, Ogata T, Kingaku M, Kaino A, Miyauchi H, Fukuwatari Y, Shimamura S. 1995. Orally administered bovine lactoferrin inhibits bacterial translocation in mice fed bovine milk. Appl. Environ. Microbiol. 61:4131-4134.
6. Teraguchi S, Shin K, Ozawa K, Nakamura S, Fukuwatari Y, Tsuyuki S, Namihira H, Shimamura S. 1995. Bacteriostatic effect of orally administered bovine lactoferrin on proliferation of Clostridium species in the gut of mice fed bovine milk. Appl. Environ. Microbiol. 61:501- 506.
7. Teraguchi S, Wakabayashi H, Kuwata H, Yamauchi K, Tamura Y. 2004. Protection against infectionsbyoral lactoferrin: evaluation inanimalmodels. Biometals 17:231-234. http://dx.doi.org/10.1023/B:BIOM.0000027697.83706.32.
8. Zimecki M, Kapp J, Machnicki M, Zagulski T, Wlaszczyk A, Kubler A, Mazurier J, Spik G. 1998. Lactoferrin. Its role in maturation and function of cells of the immune system and protection against shock in mice. Adv. Exp. Med. Biol. 443:331-336.
9. Yamaguchi N, Kieba IR, Korostoff J, Howard PS, Shenker BJ, Lally ET. 2001. Maintenance of oxidative phosphorylation protects cells from Actinobacillus actinomycetemcomitans leukotoxin-induced apoptosis. Cell. Microbiol. 3:811-823. http://dx.doi.org/10.1046/j.1462-5822.2001.00161.x.
10. Bhimani RS, Vendrov Y, Furmanski P. 1999. Influence of lactoferrin feeding and injection against systemic staphylococcal infections in mice. J. Appl. Microbiol. 86:135-144. http://dx.doi.org/10.1046/j.1365-2672.1999.00644.x.
11. Velusamy S, Ganeshnarayan K, Markowitz K, Schreiner H, Furgang D, Fine DH, Velliyagounder K. 2013. Lactoferrin knockout mice demonstrate greater susceptibility to Aggregatibacter actinomycetemcomitansinduced periodontal disease. J. Periodontol. 84:1690-1701. http://dx.doi.org/10.1902/jop.2013. 120587.
12. Ward PP, Mendoza-Meneses M, Cunningham GA, Conneely OM. 2003. Iron status in mice carrying a targeted disruption of lactoferrin. Mol. Cell. Biol. 23:178-185. http://dx.doi.org/10.1128/MCB.23.1.178-185.2003.
13. Schreiner H, Markowitz K, Miryalkar M, Moore D, Diehl S, Fine DH. 2011. Aggregatibacter actinomycetemcomitans-induced bone loss and antibody response in three rat strains. J. Periodontol. 82:142-150. http://dx.doi.org/10.1902/jop. 2010.100250.
14. van den Berg S, Laman JD, Boon L, ten Kate MT, de Knegt GJ, Verdijk RM, Verbrugh HA, Nouwen JL, Bakker-Woudenberg IA. 2013. Distinctive cytokines as biomarkers predicting fatal outcome of severe Staphylococcus aureus bacteremia in mice. PLoS One 8:e59107. http://dx.doi.org/10.1371/journal.pone.0059107.
15. Tang G, Kitten T, Munro CL, Wellman GC, Mintz KP. 2008. EmaA, a potential virulence determinant of Aggregatibacter actinomycetemcomitans in infective endocarditis. Infect. Immun. 76:2316-2324. http://dx.doi.org/10.1128/IAI.00021- 08.
16. Tang G, Mintz KP. 2010. Glycosylation of the collagen adhesin EmaA of Aggregatibacter actinomycetemcomitans is dependent upon the lipopolysaccharide biosynthetic pathway. J. Bacteriol. 192:1395-1404. http://dx.doi.org/10.1128/JB. 01453-09.
17. Zhang T, Kurita-Ochiai T, Hashizume T, Du Y, Oguchi S, Yamamoto M. 2010. Aggregatibacter actinomycetemcomitans accelerates atherosclerosis with an increase in atherogenic factors in spontaneously hyperlipidemic mice. FEMS Immunol. Med. Microbiol. 59:143-151. http://dx.doi.org/10.1111/j.1574-695X.2010. 00674.x.
18. Rahamat-Langendoen JC, van Vonderen MG, Engstrom LJ, Manson WL, van Winkelhoff AJ, Mooi-Kokenberg EA. 2011. Brain abscess associated with Aggregatibacter actinomycetemcomitans: case report and review of literature. J. Clin. Periodontol. 38:702-706. http://dx.doi.org/10.1111/j.1600-051X.2011.01737. x.
19. Machnicki M, Zimecki M, Zagulski T. 1993. Lactoferrin regulates the release of tumour necrosis factor alpha and interleukin 6 in vivo, Int. J. Exp. Pathol. 74:433-439.
20. Miyauchi H, Hashimoto S, Nakajima M, Shinoda I, Fukuwatari Y, Hayasawa H. 1998. Bovine lactoferrin stimulates the phagocytic activity of human neutrophils: identification of its active domain. Cell. Immunol. 187:34-37. http://dx.doi.org/10.1006/cimm.1997.1246.
21. Sanchez L, Calvo M, Brock JH. 1992. Biological role of lactoferrin. Arch. Dis. Child. 67:657-661. http://dx.doi.org/10.1136/adc.67.5.657.
22. Bellamy W, Takase M, Yamauchi K, Wakabayashi H, Kawase K, Tomita M. 1992. Identification of the bactericidal domain of lactoferrin. Biochim. Biophys. Acta 1121:130-136. http://dx.doi.org/10.1016/0167-4838(92)90346-F.
23. Baveye S, Elass E, Mazurier J, Spik G, Legrand D. 1999. Lactoferrin: a multifunctional glycoprotein involved in the modulation of the inflammatory process. Clin. Chem. Lab. Med. 37:281-286.
24. Spagnuolo PA, Hoffman-Goetz L. 2008. Dietary lactoferrin does not prevent dextran sulfate sodium induced murine intestinal lymphocyte death. Exp. Biol. Med. (Maywood) 233:1099-1108. http://dx.doi.org/10.3181/0802-RM-53.
25. Crouch SP, Slater KJ, Fletcher J. 1992. Regulation of cytokine release from mononuclear cells by the iron-binding protein lactoferrin. Blood 80:235-240.
26. Zimecki M, Artym J, Chodaczek G, Kocieba M, Kruzel M. 2005. Effects of lactoferrin on the immune response modified by the immobilization stress. Pharmacol. Rep. 57:811-817. http://www.if-pan.krakow.pl/pjp/pdf/2005/6-811.pdf.
27. Haversen LA, Baltzer L, Dolphin G, Hanson LA, Mattsby-Baltzer I. 2003. Anti-inflammatory activities of human lactoferrin in acute dextran sulphate-induced colitis in mice. Scand. J. Immunol. 57:2-10. http://dx.doi.org/10.1046/j.1365-3083.2003.01162.x.
28. Kruzel ML, Actor JK, Boldogh I, Zimecki M. 2007. Lactoferrin in health and disease. Postepy Hig. Med. Dosw. 61:261-267. http://www.phmd.pl/pub/phmd/ vol-61/10398.pdf.
29. van der Does AM, Hensbergen PJ, Bogaards SJ, Cansoy M, Deelder AM, van Leeuwen HC, Drijfhout JW, van Dissel JT, Nibbering PH. 2012. The human lactoferrin-derived peptide hLF1-11 exerts immunomodulatory effects by specific inhibition of myeloperoxidase activity. J. Immunol. 188:5012-5019. http://dx.doi.org/10.4049/jimmunol.1102777.
30. Maccio A, Madeddu C, Gramignano G, Mulas C, Sanna E, Mantovani G. 2010. Efficacy and safety of oral lactoferrin supplementation in combination with rHuEPO-beta for the treatment of anemia in advanced cancer patients undergoing chemotherapy: open-label, randomized controlled study. Oncologist 15:894-902. http://dx.doi.org/10.1634/theoncologist.2010-0020.
31. Sosroseno W, Musa M, Ravichandran M, Ibrahim MF, Bird PS, Seymour GJ. 2008. Effect of inhibition of inducible nitric oxide synthase (iNOS) on the murine splenic immune response induced by Aggregatibacter (Actinobacillus) actinomycetemcomitans lipopolysaccharide. Eur. J. Oral Sci. 116:31-36. http://dx.doi.org/10.1111/j.1600-0722.2007.00501.x.
32. Sosroseno W, Bird PS, Seymour GJ. 2009. Effect of exogenous nitric oxide on murine splenic immune response induced by Aggregatibacter actinomycetemcomitans lipopolysaccharide. Anaerobe 15:95-98. http://dx.doi.org/10.1016/j.anaerobe.2009.01.002.
33. Chen LT, Lu L, Broxmeyer HE. 1987. Effects of purified iron-saturated human lactoferrin on spleen morphology in mice infected with Friend virus complex. Am. J. Pathol. 126:285-292.
34. Zimecki M, Miedzybrodzki R, Mazurier J, Spik G. 1999. Regulatory effects of lactoferrin and lipopolysaccharide on LFA-1 expression on human peripheral blood mononuclear cells. Arch. Immunol. Ther. Exp. (Warsz.) 47:257-264.
35. Zimecki M, Artym J, Chodaczek G, Kocieba M, Kruzel ML. 2004. Protective effects of lactoferrin in Escherichia coli-induced bacteremia in mice: relationship to reduced serum TNF alpha level and increased turnover of neutrophils. Inflamm. Res. 53:292-296. http://dx.doi.org/10.1007/s00011-004- 1257-1.
36. Leon-Sicairos N, Martinez-Pardo L, Sanchez-Hernandez B, de la Garza M, Carrero JC. 2012. Oral lactoferrin treatment resolves amoebic intracecal infection in C3H/HeJ mice. Biochem. Cell Biol. 90:435-441. http://dx.doi.org/10. 1139/o2012-008.
37. Welsh KJ, Hwang SA, Boyd S, Kruzel ML, Hunter RL, Actor JK. 2011. Influence of oral lactoferrin on Mycobacterium tuberculosis induced immunopathology. Tuberculosis (Edinb.) 91(Suppl 1):S105-S113. http://dx.doi.org/10.1016/j.tube.2011.10.019.
38. Drago-Serrano ME, Rivera-Aguilar V, Resendiz-Albor AA, Campos- Rodriguez R. 2010. Lactoferrin increases both resistance to Salmonella typhimurium infection and the production of antibodies in mice. Immunol. Lett. 134:35-46. http://dx.doi.org/10.1016/j.imlet.2010.08.007.
39. Lee HY, Park JH, Seok SH, Baek MW, Kim DJ, Lee BH, Kang PD, Kim YS, Park JH. 2005. Potential antimicrobial effects of human lactoferrin against oral infection with Listeria monocytogenes in mice. J. Med. Microbiol. 54:1049-1054. http://dx.doi.org/10.1099/jmm.0.45918-0.
40. Shin K, Wakabayashi H, Yamauchi K, Teraguchi S, Tamura Y, Kurokawa M, Shiraki K. 2005. Effects of orally administered bovine lactoferrin and lactoperoxidase on influenza virus infection in mice. J. Med. Microbiol. 54:717-723. http://dx.doi.org/10.1099/jmm.0.46018-0.
41. Takakura N, Wakabayashi H, Ishibashi H, Yamauchi K, Teraguchi S, Tamura Y, Yamaguchi H, Abe S. 2004. Effect of orally administered bovine lactoferrin on the immune response in the oral candidiasis murine model. J. Med. Microbiol. 53:495-500. http://dx.doi.org/10.1099/jmm.0.05505-0.
42. Togawa J, Nagase H, Tanaka K, Inamori M, Nakajima A, Ueno N, Saito T, Sekihara H. 2002. Oral administration of lactoferrin reduces colitis in rats via modulation of the immune system and correction of cytokine imbalance. J. Gastroenterol. Hepatol. 17:1291-1298. http://dx.doi.org/10.1046/j.1440-1746. 2002.02868.x.
43. Zagulski T, Jarzabek Z, Zagulska A, Jaszczak M, Kochanowska IE, Zimecki M. 2001. Lactoferrin stimulates killing and clearance of bacteria but does not prevent mortality of diabetic mice. Arch. Immunol. Ther. Exp. (Warsz.) 49:431-438.
44. Zimecki M, Artym J, Kocieba M, Weber-Dabrowska B, Lusiak- Szelachowska M, Gorski A. 2008. The concerted action of lactoferrin and bacteriophages in the clearance of bacteria in sublethally infected mice. Postepy Hig. Med. Dosw. 62:42-46. http://www.phmd.pl/pub/phmd/vol-62/11539.pdf.
45. Yamaguchi M, Matsuura M, Kobayashi K, Sasaki H, Yajima T, Kuwata T. 2001. Lactoferrin protects against development of hepatitis caused by sensitization of Kupffer cells by lipopolysaccharide. Clin. Diagn. Lab. Immunol. 8:1234-1239. http://dx.doi.org/10.1128/CDLI.8.6.1234-1239.2001.
46. Palumbo D, Iannaccone M, Porta A, Capparelli R. 2010. Experimental antibacterial therapy with puroindolines, lactoferrin and lysozyme in Listeria monocytogenes-infected mice. Microbes Infect. 12:538-545. http://dx.doi.org/10. 1016/j.micinf.2010.03.010.
47. Zagulski T, Lipinski P, Zagulska A, Jarzabek Z. 1998. Antibacterial system generated by lactoferrin in mice in vivo is primarily a killing system. Int. J. Exp. Pathol. 79:117-123.
48. Rivera FP, Medina AM, Bezada S, Valencia R, Bernal M, Meza R, Maves RC, Ochoa TJ. 2013. Bovine lactoferrin decreases cholera-toxin-induced intestinal fluid accumulation in mice by ganglioside interaction. PLoS One 8:e59253. http://dx.doi.org/10.1371/journal.pone.0059253.
49. Brouwer CP, Welling MM. 2008. Various routes of administration of (99m)Tc-labeled synthetic lactoferrin antimicrobial peptide hLF 1-11 enables monitoring and effective killing of multidrug-resistant Staphylococcus aureus infections in mice. Peptides 29:1109-1117. http://dx.doi.org/10.1016/j.peptides. 2008.03.003.
50. Zagulski T, Lipinski P, Zagulska A, Broniek S, Jarzabek Z. 1989. Lactoferrin can protect mice against a lethal dose of Escherichia coli in experimental infection in vivo. Br. J. Exp. Pathol. 70:697-704.